ACXP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ACXP is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has some speculative biotech upside from pipeline news and a government grant, but the overall setup is weak: the trend is bearish, analyst expectations have been cut sharply, earnings remain deeply negative, and the recent pattern suggests further downside. Since there is no strong Intellectia buy signal today and the current price is sitting below a bearish moving-average structure, the better call is to hold off rather than buy now.
Price is 2.06 versus a prior close of 2.09, with mixed short-term movement and a weak broader setup. MACD histogram is positive at 0.0232 and expanding, which is a mild bullish momentum sign, but RSI_6 at 45.42 is neutral and not showing strong demand. The moving averages are bearish with SMA_200 > SMA_20 > SMA_5, indicating the longer-term trend is still down. Pivot is 2.103, so the stock is trading slightly below the pivot, with resistance at 2.241 and support at 1.966. Overall technicals remain weak, and the modeled trend points to downside over the near term.
["Acurx's DNA pol IIIC inhibitors showed promise in preserving gut microbiome structure while treating resistant Gram-positive infections.", "Researchers announced a novel antibiotic approach that selectively targets systemic bacterial pathogens without harming beneficial gut bacteria.", "Acurx received a new research grant from the Dutch government to support development of DNA pol IIIC inhibitors.", "Pipeline exposure to resistant-bacteria indications such as MRSA could create future upside if development progress continues."]
["Alliance Global cut its price target to $10 from $20, reflecting reduced optimism after the Q4 report.", "Expected FDA approval for ibezapolstat was pushed back to 2031 from 2028, a significant delay.", "The company is still unprofitable, with Q4 net income of -1.58M and EPS of -0.73, both deteriorating year over year.", "Revenue is still 0, so there is no commercial growth base yet.", "Bearish moving averages and a weak pattern-based forecast suggest downside risk remains elevated.", "No meaningful hedge fund, insider, or congress trading support is visible.", "AI Stock Picker gave no signal today and SwingMax gave no recent signal."]
In Q4 2025, Acurx reported revenue of 0, unchanged year over year, so there is no sales traction yet. Net income fell to -1,578,276, down 43.26% YoY, and EPS dropped to -0.73, down 77.81% YoY. Gross margin was 0 because there is no revenue. For a beginner long-term investor, the latest quarter shows continued cash burn rather than improving operating momentum.
Alliance Global lowered its price target to $10 from $20 while keeping a Buy rating, which is still constructive but clearly less aggressive than before. The main change is a much later expected FDA approval timeline, now 2031 instead of 2028. Wall Street’s pros view is that the science still has promise and the new Phase 2 path may generate data faster and cheaper; the cons view is that the delay materially slows the investment case and reinforces the speculative nature of the stock.
